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A B S T R A C T
There is an urgent need for therapies that could reduce the disease burden of preterm hypoxic-ischemic en-
cephalopathy. Here, we evaluate the long-term eﬀects of multipotent adult progenitor cells (MAPC) on long-term
behavioral outcomes in a preterm rat model of perinatal asphyxia. Rats of both sexes were treated with two doses
of MAPCs within 24 h after the insult. Locomotor, cognitive and psychiatric impairments were evaluated starting
at 1.5 (juvenile) and 6 months (adult). Hypoxia-ischemia aﬀected locomotion, cognition, and anxiety in a sex-
dependent manner, with higher vulnerability observed in males. The MAPC therapy partially attenuated deﬁcits
in object recognition memory in females of all tested ages, and in the adult males. The hypoxic insult caused
delayed hyperactivity in adult males, which was corrected by MAPC therapy. These results suggest that MAPCs
may have long-term beneﬁts for neurodevelopmental outcome after preterm birth and global hypoxia-ischemia,
which warrants further preclinical exploration.
1. Introduction
Preterm birth is a major worldwide healthcare challenge, with
11.1% of all births occurring before 37 weeks of gestation, and 1–2%
before 28 weeks [1,2]. Preterm infants often complicate with en-
cephalopathy, due to a combination of immaturity and injurious events
around birth - such as hypoxia-ischemia (HI), inﬂammation or infec-
tion. Pathologically encephalopathy is characterized by diﬀuse injury to
the white matter of the brain, accompanied by secondary injury to the
gray matter [3–5]. This has devastating consequences, especially at a
very low gestational age (VLGA), below 28 weeks at birth, where en-
cephalopathy leads to lasting functional impairments in almost half of
survivors [6].
Unfortunately, therapeutic options for preterm encephalopathy are
limited to supportive care, however neuroprotective strategies such as
bone-marrow derived stem cell therapies are under evaluation for this
group of patient [7]. More precisely, previous studies reported that
multipotent adult progenitor cells (MAPCs) or mesenchymal stem cells
(MSCs), reduce acute neurological injury after HI in the preterm sheep
brain [8,9]. MAPCs have the advantages of a lower immunogenicity
and a higher proliferation capacity as compared to MSCs, which are
important for clinical translation [10]. Several studies have shown that
MSCs and MAPCs can improve functional outcomes in rodent models of
late-preterm neurological injury [11–15]. However, it has not yet been
established whether these cells are also beneﬁcial for an insult in the
VLGA brain.
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We used diﬀerences in brain development between rats and humans
to address this question. The rat is an ideal model to study the long-term
eﬃcacy of therapies for VLGA insults, because the rat brain develop-
ment at birth resembles the brain at 23 weeks of gestation in the
human, and rats can be followed up across key human life stages [16].
Rats reach sexual maturity equivalent to adolescence around 1.5
months of age, but only reach the social maturity of early adulthood
around 5–6 months of age [17]. The aim of this study was to explore
functional deﬁcits which may be amendable by MAPC administration at
birth. We administered two doses of MAPCs within 24 h of a global HI
insult at birth [16]. Here we report the eﬀects of this therapy on lo-
comotion, cognition, anxiety during adolescence (1.5–3 months) and
adulthood (6–7.5 months) in the rat.
2. Materials and methods
2.1. Perinatal asphyxia (PA) procedure
Sprague-Dawley rats from Charles River (Leiden, The Netherlands)
were used for these experiments. Rats were housed at the Central
Animal Experimentation Facilities of the Maastricht University, The
Netherlands. All experiments were conducted under Dutch Ethical ap-
proval according to the guidelines of the EU directive 2010/63/EU.
Female rats were time-mated. In the afternoon of embryonic day 21
(expected delivery on E21–E22), the pregnant rat was euthanized by
rapid decapitation and the uterine horns, still containing the pups, ra-
pidly removed and submerged in saline solution at 37 °C for 16–18min
according to previously described methodology [18,19], with the
groups distributed evenly over diﬀerent durations. After submersion,
the pups were delivered manually, stimulated to breathe and placed in
a closed pediatric incubator to recover for an hour (at 37 °C), before
being placed with a foster mother that had given birth the day before.
Control rats were delivered through C-section from the same litters
without going through the submersion process.
2.2. Preparation and administration of MAPCs
Human non-clinical grade MAPCs were obtained from Athersys, Inc.
(Cleveland, USA) and stored in liquid nitrogen until resuspension in
saline. 200,000 viable cells in 24 μl saline or saline were administered
via subcutaneous injection in the neck fold at 6 and 24 h after birth to
the HI-exposed groups. The control C-section group did not receive
treatment.
2.3. Behavior testing
The rats were housed in pairs after weaning. Two weeks before
testing, the day night cycle was reversed. Three groups of rats were
tested: MAPC-treated HI rats (12 males, 12 females), vehicle-treated HI
rats (12 males, 11 females) and C-section controls (12 males, 13 fe-
males). The behavioral tests were performed at 1.5–3 months (juvenile
to young adulthood) and at 6–7.5 months of age (older adulthood). The
serial testing approach was scheduled from the least stressful to the
most stressful.
Locomotion was evaluated with a 40min open ﬁeld test in a
100 cm×100 cm plexiglass arena divided into 4 smaller 50 cm×50
cm arenas. Total distance moved was tracked with the EthoVision 8.5
software (Noldus, The Netherlands). Object recognition memory was
assessed with testing at a delay of 4 h as previously described (Strackx
et al., 2010). In the adult group, we used 4 additional novel objects in
the second trial. The discrimination index (d2) was calculated from the
time spent exploring the new object minus time spent exploring the old
object, divided by the total exploration time as scored by two blinded
observers. Rats which exhibited total exploration times of less than 8 s
in the second trial were excluded from analysis. D2 values signiﬁcantly
greater than zero indicate intact recognition memory [19].
Anxiety-related behavior was evaluated with the elevated zero maze
(EZM) as previously described [19] and the home-cage emergence
(HCE) test. Prior to the HCE test, the rats were single-housed overnight.
The cage was placed in the arena with lighting on the cage but not the
part of the arena directly behind the cage. A wire grid was placed in the
cage to aid the escape from the lit home cage to the dark arena. An
escape was deﬁned as having all four paws on the grid outside the cage.
The latency to escape was timed for up to 10min.
2.4. Statistics
Statistical calculations were performed with Stata10 (Statacorp,
College Station, TX, USA). Graphs of average ± S.E.M were made with
GraphPad Prism 6 (GraphPad, San Diego, CA, USA). Results were
analyzed with a repeated-measures ANOVA with age as a within sub-
jects factor and treatment group (vehicle-treated HI, MAPC-treated HI
or C-section), sex as between-group factors. Post-hoc comparisons be-
tween groups were done with t-tests. Results from the object recogni-
tion test were also analyzed with two-sided paired t-tests against a
matrix of zeros. P-values< 0.05 were considered to be statistically
signiﬁcant.
3. Results
3.1. Mortality and body weights of the rats
The pre-weaning mortality rate for the HI procedure was 39% and it
was similar between groups since the majority of deaths occurred be-
fore treatment was initiated at 6 h after birth. One additional vehicle-
treated HI rat was euthanized due to complications associated with an
enlarged thymus gland. Over the study period, the males were con-
sistently heavier than the female rats (p < 0.001) and the rats con-
tinued gaining weights as they aged (p < 0.001), but the HIE- and
treatment had no eﬀect on weight (p=0.4457, Supplementary Fig. 1).
3.2. Locomotion
We assessed locomotor deﬁcits with the open ﬁeld test (Fig. 1).
Overall, the juvenile rats moved more than the adult rats (ALL juvenile
vs. ALL adult, p < 0.001) and females moved more than males (ALL
[F] vs. ALL [M], p < 0.001).
Fig. 1. The total distance moved in 40min showed an eﬀect of asphyxia in
juvenile females, but not of the treatment group. HI-induced hyperlocomotion
in the adult male group was corrected by the MAPC therapy (* p < 0.05).
Group sizes: HI-MAPC-treated rats (12 males, 12 females), HI-vehicle-treated
rats (12 males, 11 females) and C-section controls (12 males, 13 females).
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In the adult male rats, vehicle-treated HI animals covered a sig-
niﬁcant greater distance than the C-section control animals (CTR [M]
vs. HI-VEH [M], p=0.022), indicating HI-associated hyperlocomotion
in adult males. MAPC treatment signiﬁcantly reduced hyperlocomotion
after global HI in adult males (HI-VEH [M] vs. HI-MAPC [M],
P=0.0021). No signiﬁcant diﬀerence in locomotion was found be-
tween the control and treatment group (CTR [M] vs. HI-MAPC [M],
p=0.091) in adult males, which indirectly conﬁrms the treatment ef-
fect.
In the juvenile female rats, HI induced signiﬁcant hypolocomotion
(CTR [F] vs. HI-VEH [F], p= 0.011). But, the MAPC therapy did not
change HI-associated hypolocomotion in juvenile female rats (HI-VEH
[F] vs. HI-MAPC [F] p=0.191, and CTR [F] vs. HI-MAPC [F]
p=0.011). No signiﬁcant diﬀerences in locomotion between experi-
mental groups were seen in juvenile males or adult females.
3.3. Recognition memory
We assessed deﬁcits in recognition memory assessed with the object
recognition test. We evaluated both the presence of an intact recogni-
tion memory (d2-discrimination index> 0, p (paired t-test)< 0.05)
and diﬀerences in the extent of recognition memory between groups
(ANOVA & post-hoc t-test p < 0.05). At the juvenile-time point, the
vehicle-treated HI groups and male MAPC-treated HI groups did not
recall the original object (HI-VEH [M] & HI-VEH [F] & HI-MAPC [M],
d2 > 0, p=not signiﬁcant), but both male and female control rats, as
well as the female MAPC-treated HI group, had an intact recognition
memory (CTR [M] & CTR [F] & HI-MAPC [F], d2 > 0, p < 0.05). This
indicates that the HI-insult impaired recognition memory relative to the
controls, and the MAPC-therapy restored this in the females, but not in
the males. In the adult group, all female rats had an intact recognition
memory (CTR [F] & HI-VEH [F] & HI-MAPC [F] d2 > 0, p < 0.05). In
the males, the vehicle-HI-group forgot (HI-VEH d2 > 0 p=not sig-
niﬁcant), but both the control and MAPC-treated HI rats remembered
(CTR [M] & HI-MAPC [M] d2 > 0, p < 0.05). This indicates that the
vehicle treated HI females recovered their memory in the second round
of testing, whilst the vehicle treated HI males remained impaired,
which the MAPC-therapy restored.
Assessing diﬀerences in the magnitude of recognition with an
ANOVA showed that the overall d2-scores were not aﬀected by sex or
age. Group diﬀerences were only signiﬁcant in the juvenile male rats,
where the HI-exposed groups performed worse than the C-section group
(CTR [M] vs. HI-VEH [M], p=0.012, CTR [M] vs. HI-MAPC [M],
p=0.034), but there were no diﬀerences between the MAPC-treated
and vehicle-treated HI groups (HI-VEH [M] vs. HI-MAPC [M]
p=0.231). There were no signiﬁcant diﬀerences between groups for
the adult male rats (p= 0.107–0.265), juvenile female rats
(p= 0.068–0.449) or the adult female rats (p= 0.325–0.517) (Fig. 2).
This indicates that the beneﬁt of the MAPC-therapy was suﬃcient to
improve the presence of an intact recognition memory (measured with
the d2 > 0 test), but not suﬃcient to improve the magnitude of re-
cognition memory between groups, thus conferring a partial beneﬁt.
3.4. The home-cage emergence test
In the home-cage emergence test (Fig. 3), the females emerged
much quicker than males (ALL [F] vs. ALL [M], p < 0.001) and la-
tencies were similar between ages (ALL juvenile vs. ALL adult,
p= 0.700). A group eﬀect was only seen in the juvenile females, where
the HI-exposed groups were quicker to escape than the C-section con-
trol group (HI-VEH CTR [F] p=0.024; HI-MAPC [F] vs. CTR [F]
p=0.004), but there were no signiﬁcant diﬀerences between the HI-
exposed groups (HI-VEH [F] vs. HI-MAPC [F], p= 0.337). Thus, whilst
HI had an eﬀect on emergence, there was no eﬀect related to MAPC
therapy.
3.5. The elevated zero maze
This test was only conducted in the adult group. There were no
overall signiﬁcant diﬀerences in time spent in either arm due to the
group (p=0.360) or sex (p=0.228) (Fig. 4).
4. Discussion
Encephalopathy of prematurity is a multifactorial insult resulting
from a primary insult due to the underdeveloped brain and secondary
HI and inﬂammatory insults [7]. We investigated MAPCs as a ther-
apeutic option for encephalopathy caused by a moderate global HI in-
sult in the newborn immature rat. Brain development in this model
resembles the human situation at 23-weeks of gestation in terms of
Fig. 2. The discriminatory index after 4 h delay showed a partial rescue of re-
cognition memory in both juvenile and adult females and adult males (* or **
indicates values higher than 0 with a two-tailed paired t-test (*p < 0.05, **
p < 0.01)). There were no signiﬁcant diﬀerences observed between HI-MAPC-
treated and HI-vehicle-treated rats, as determined with a post-hoc t-test at any
time point for both sexes. Group sizes: HI-MAPC-treated rats (12 males, 12
females), HI-vehicle-treated rats (12 males, 11 females) and C-section controls
(12 males, 13 females).
Fig. 3. The home-cage emergence task showed sex diﬀerences in the latency to
emerge, but no beneﬁt of the therapy (* p < 0.05). Group sizes: HI-MAPC-
treated rats (12 males, 12 females), HI-vehicle-treated rats (12 males, 11 fe-
males) and C-section controls (12 males, 13 females).
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oligodendrocyte maturation, immune system development and the es-
tablishment of the blood-brain barrier [20]. We showed that MAPC
therapy partially attenuated long-term neurodevelopmental deﬁcits
with testing ages up to 8 months. We found a persistent cognitive rescue
by the MAPCs in the female rats of both age groups, but to a lesser
extent in the male rats where only the adult rats responded. For the
locomotor outcomes, we found that overall HI reduced movement, and
MAPCs did not rescue this. However, the adult male HI-group had a
delayed hyperactivity which could represent a delayed onset of a hy-
peractivity disorder, which was rescued by the MAPC therapy. The cells
had no eﬀect on anxiety-related measures. The sex diﬀerences we ob-
served in both HI-severity and therapeutic response is reminiscent of
the clinical scenario where male infants have more mortality and
morbidity after encephalopathy than females, but females have pro-
longed increased pain sensitivity [18,21,22].
We provided the ﬁrst long-term follow-up data with minimally in-
vasively administered MAPCs in a neonatal rat model. A previous study
using MAPCs in rats with focal neonatal stroke at term showed im-
provements in neurological scores at 2 weeks after the insult [23]. In
preterm global HI, the MAPCs reduced seizure burden, inﬂammation
and disturbances in myelination at 1 week after the insult [8]. Of note,
the MAPCs are currently being studied in human clinical trials for adult
ischemic stroke, myocardial infarctions, inﬂammatory bowel disease
and graft vs. host disease. The MAPCs are well tolerated in the tested
adult populations [24–26]. A clinical study, and previous preclinical
studies in adult ischemic stroke and traumatic brain injury, show that
the MAPCs have a potent immunomodulatory eﬀect via interaction
with the spleen, which translates into a decreased overall hospitaliza-
tion time for patients [25,27], and reduced lesion size with resulting
improved locomotor and neurological scores in rodents [27–29]. MSCs
have been more extensively studied in neonatal models. The majority of
neonatal MSC studies have focused on focal brain injury, where MSCs
improve long-term locomotor, sensorimotor and cognitive outcomes in
rodents up to 14 months of age, despite not diﬀerentiating into func-
tional neural cells in vivo [15,30–32]. Together with our data, this
suggests that stem cell therapies, particularly the MAPCs, show bene-
ﬁcial neurological eﬀects.
An acute HI insult damages the brain in three phases [33]. Directly
after the insult, during the primary phase, high-energy metabolites are
depleted. This leads to progressive depolarization of cells, extracellular
accumulation of excitatory amino acids, acidosis and cytotoxic edema.
Most neurons survive this stage, only to succumb during the second
phase of injury due to cerebral energy failure from 6 to 15 h after birth.
The tertiary phase predominantly consists of repair and rewiring.
During this period, physiological apoptosis continues to be upregulated
which can lead to ongoing cell loss occurring several months after the
insult [33,34]. The severity of the secondary phase of HI-injury is clo-
sely correlated with later neurodevelopmental impairment [35]. Based
on these ﬁndings, we choose to administer two doses of 200,000 MAPCs
(˜40 million/kg in a 5 g newborn pup) administered within 24 h coin-
ciding with the secondary (6 h) and recovery phase (24 h) after HI-in-
jury [34]. Our dosage selection was based on the previous MAPC data
in a rat model of focal neonatal stroke [23]. Previous studies with
MAPCs in a model of global HI in the preterm sheep showed that re-
peated administration has beneﬁcial eﬀects on structural and functional
recovery [8] and combining an earlier dose with a dose at 24 h after the
insult is beneﬁcial in models of adult traumatic brain injury [36,37].
We hypothesized that a second dose confers additional beneﬁt since
stem cells adapt their growth and diﬀerentiation factor production ac-
cording to the needs of the environment at the time of administration,
which has been shown with MSCs [31]. We showed partial attenuation
of functional deﬁcits at these doses, which could be further explored
with diﬀerent dosage regimens. The limitations of our behavioral
testing were that maturation occurred over the testing period and that
the juvenile tests were repeated in the adult rats. However, the in-
dividual tests were conducted within a week and the rats had a period
of 2.5 months between testing sessions to limit the eﬀect of these
confounders.
The strength of our study lies on its potential for clinical translation.
We utilized a minimally invasive administration route at the clinically
feasible time-points of 6 and 24 h after the insult, which gives clinicians
time to establish a diagnosis. We further used a model of a moderate
global HI insult on top of an already underdeveloped brain, which
mimics the often global nature of clinical neonatal brain injury [16].
Our results show that MAPC therapy has promise in attenuating the
disability burden of encephalopathy of prematurity which warrants
further preclinical development.
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